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P-glycoprotein (P-gp) is a plasma membrane glycoprotein that can cause multidrug resistance (MDR) of cancer cells by acting as an ATP-
dependent drug efflux pump. The regulatory effects of the small GTPases Rab5 and RalA on the intracellular trafficking of P-gp were investigated
in HeLa cells. As expected, overexpressed enhanced green fluorescent protein (EGFP)-tagged P-gp (P-gp-EGFP) is mainly localised to the plasma
membrane. However, upon cotransfection of either dominant negative Rab5 (Rab5-S34N) or constitutively active RalA (RalA-G23V) the
intracellular P-gp-EGFP levels increased approximately 9 and 13 fold, respectively, compared to control P-gp-EGFP cells. These results suggest
that Rab5 and RalA regulate P-gp trafficking between the plasma membrane and an intracellular compartment. In contrast, coexpression of
constitutively active Rab5 (Rab5-Q79L) or dominant negative RalA (RalA-S28N) had no effect on the localisation of P-gp-EGFP. Furthermore,
the intracellular accumulation of daunorubicin, a substrate for P-gp, increased significantly with an increased intracellular localisation of P-gp-
EGFP. These results imply that it may be possible to overcome MDR by controlling the plasma membrane localisation of P-gp.
© 2007 Elsevier B.V. All rights reserved.Keywords: P-glycoprotein; endocytosis; exocytosis; Rab5; RalA; multidrug resistance in cancer1. Introduction
Multidrug resistance (MDR) has been a major obstacle in
cancer chemotherapy. One of the major causes of MDR is over-
expression of P-glycoprotein (P-gp), amembrane protein encoded
by the human mdr1 gene, whereby tumour cells become drug
resistant [1,2]. Overexpression of themdr1 gene is found in many
different cancers, including tumours not previously exposed to
chemotherapy [3]. P-gp acts as a drug efflux pump to transport a
wide range of chemotherapeutic drugs, differing both structurally
and in their mechanism of action, out of drug resistant cancer
cells. Consequently, cancer cells continue to proliferate. In order
to inhibit or interrupt the transport activity of P-gp, chemosensi-
tizers or P-gp modulators have been used but these methods give⁎ Corresponding author. Tel.: +61 2 9351 2831; fax: +61 2 9351 4447.
E-mail address: basilr@pharm.usyd.edu.au (B.D. Roufogalis).
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doi:10.1016/j.bbamcr.2007.03.023unwanted side effects. Since P-gp needs to be present on the
plasma membrane to act as a drug efflux pump [4], an alternative
way to regulate P-gp activity could be to interfere with its plasma
membrane localisation.
Membrane proteins and cargo molecules are transported
from one membrane compartment to another by mobilisation of
membrane structures and vesicular transport [5,6]. Petriz and
co-workers demonstrated that EGFP-tagged P-gp (P-gp-EGFP)
was mainly localised at the plasma membrane and the Golgi
apparatus and there was an inverse relationship between P-gp-
EGFP expression and nuclear doxorubicin accumulation [7].
Our previous study showed that P-gp-EGFP is transported to the
plasma membrane via the endoplasmic reticulum (ER) and the
Golgi apparatus [4]. Upon reaching the plasma membrane, P-gp
continuously cycles between the plasma membrane and
endosomal compartments [8,9]. When the transport of newly
synthesized P-gp-EGFP to the plasma membrane was blocked
by brefeldin A (BFA) or monensin, we found an increased
Fig. 1. Localisation of Rab5 and RalA mutants in HeLa cells. HeLa cells were
transfected with HA-Rab5-Q79L (A), HA-Rab5-S34N (B), HA-RalA-G23V
(C) and HA-RalA-S28N (D). Cells were fixed and immunolabelled for Rab5
(A, B) or RalA (C, D). Bar, 5 μm.
Fig. 2. Rab5-Q79L does not affect the localisation of P-gp-EGFP. HeLa cells
were transfected with P-gp-EGFP alone (A) or P-gp-EGFP and HA-Rab5-Q79L
(B–D). Cells were fixed and immunostained for Rab5 (B–C) or EEA1 (D) (red).
Merged images are shown. Bar, 5 μm.
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[4]. Likewise, interfering with endocytosis of P-gp should alter
the localisation, and therefore the activity of P-gp [9].
The Rab family of small GTPases are known to regulate
most vesicular transport events, principally by regulating
vesicle docking and fusion [10–14]. Rab proteins form the
largest branch of small GTPases, and more than 60 Rab proteins
have been discovered in mammalian cells [15]. All Rab proteins
cycle between an active GTP-bound and an inactive GDP-
bound conformation, but distinct Rab proteins are believed to be
associated with regulation of vesicle traffic from a specific
organelle or along a specific pathway [16]. Rab4, Rab5 and
Rab11 have been shown to be involved in endocytosis and
recycling to the plasma membrane [17].
Rab5 is the key regulator of membrane transport along the
endocytic pathway. Rab5 interacts with its effector early
endosome antigen 1 (EEA1), to regulate early endosome fusion
[18]. In addition, Rab5 has been shown to play a role in
endocytosis, as overexpression of dominant-negative Rab5
mutants inhibit endocytosis of several receptors, such as the
neurokinin 1 receptor, epidermal growth factor (EGF) receptor,
protease-activated receptor 2, β2-adrenergic receptor and M4
muscarinic acetylcholine receptor [19–23]. Conversely, over-
expression of wild-type Rab5 or constitutively active Rab5 has
been shown to accelerate endocytic transport [19–23], includ-
ing endocytosis of P-gp [8]. Another small GTPase, Ral, has
been shown to regulate endocytosis. There are two Ral genes,
RalA and RalB, and their encoded proteins have the same
structural organisation and share ∼ 85% protein sequence
identity [24,25] . Ral plays a role in endocytosis of a variety of
receptors such as EGF, transferrin (Tf), insulin, activin type II,
and metabotropic glutamate receptors [26–30], but the nature ofthis role is poorly understood. Conflicting reports of over-
expression of Ral mutants on endocytosis of some of these
receptors have created uncertainty [31].
In order to alter the plasma membrane localisation of P-gp,
we examined the effects of Rab5 and RalA on the intracellular
trafficking of P-gp. We found that overexpression of dominant
negative Rab5 increased the intracellular localisation of P-gp.
Furthermore, overexpression of a constitutively active RalA also
caused accumulation of P-gp in large intracellular structures. A
concomitant increase in intracellular levels of daunorubicin, a
substrate of P-gp, was found upon an increased intracellular
localisation of P-gp. These results suggest altering the
intracellular trafficking of P-gp by modulation of its small
GTPase regulators can be a potential strategy to overcomeMDR.
2. Materials and methods
2.1. Materials
HeLa cells and MCF-7 cells were purchased from the American Type
Culture Collection (ATCC, Rockville, MD). Multidrug resistance MCF-7/Adr
cells which have overexpressed wild-type P-gp were obtained from Dr. Mary
Bebawy (Faculty of Pharmacy, University of Sydney). Dulbecco's Modified
Eagle Medium (DMEM) and foetal calf serum were obtained from Invitrogen
(Carlsbad, CA). Paraformaldehyde was from ProSciTech (Thuringowa Central,
Australia). Antibody against Rab5Awas from Santa Cruz Biotechnology (Santa
Cruz, CA). Anti-RalA and anti-EEA1 were from BD Biosciences Pharmingen
(California, USA). Anti-TfR (H68.4) was from Zymed and P-gp antibody was
from Sigma. Texas Red conjugated dextran (dextran-TxR) and Texas Red
conjugated EGF (EGF-TxR) were from Molecular Probes (Eugene, OR). CY3
or Texas Red conjugated secondary antibodies were obtained from Jackson
ImmunoResearch (West Grove, PA). FuGENE 6 was from Roche and Lipofectin
was from Invitrogen (Carlsbad, CA). All other materials were obtained from
Sigma (St. Louis, MO).
Fig. 3. Rab5-S34N causes a redistribution of P-gp-EGFP to an intracellular compartment. (A) HeLa cells were transfected with P-gp-EGFP and HA-Rab5-S34N. Cells
were fixed and immunolabelled for Rab5 (red). Bar, 5 μm. (B) HeLa cells were transfected with either P-gp-EGFP alone or together with HA-Rab5-Q79L or HA-
Rab5-S34N. The intracellular fluorescent intensity of P-gp-EGFP was quantified (for details see Methods). ⁎Pb0.01, n=4. (C) HeLa cells were transfected with P-gp-
EGFP and either HA-Rab5-Q79L or HA-Rab5-S34N. The intracellular green fluorescent density (P-gp-EGFP) was measured and expressed as percentage of total
green fluorescence (for details see Materials and methods). The percentage of membrane P-gp-EGFP fluorescence was significantly decreased (Pb0.001, n=5) when
P-gp-EGFP was co-expressed with dominant negative HA-Rab5-S34N. (D–E): MCF-7/Adr cells (D) and MCF-7/Adr expressing HA-Rab5-S34N (E) were fixed and
immunolabelled for P-gp. Bar, 5 μm.
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The P-gp-EGFP plasmid has been previously described [4]. pMT2-HA-
Q79L-Rab5 (constitutively-active Rab5) and pMT2-HA-S34N-Rab5 (domi-Fig. 4. P-gp-EGFP colocalises with TfR in cells expressing Rab5-S34N. HeLa cells w
immunolabelled for TfR (B, red). (C) Merged image of A and B. Bar, 5 μm.nant-negative Rab5) were kindly provided by Johannes Bos (Laboratory for
Physiological Chemistry, Utrecht University, The Netherlands). pCGN-HA-
G23V-RalA (encoding constitutively active RalA) was provided by Akira
Kikuchi (Hiroshima University School of Medicine, Japan). To constructere transfected with P-gp-EGFP and HA-Rab5-S34N (A). Cells were fixed and
Fig. 5. Internalisation of EGF and dextran in cells expressing P-gp-EGFP and Rab5-S34N. HeLa cells were co-transfected with P-gp-EGFP and HA-Rab5-S34N. Cells
were allowed to internalise EGF-TxR (red) for 30 min (A–C) or dextran-TxR (red) for 1 h (D–F). Bar, 5 μm.
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RalA-G23V was subjected to PCR-based mutagenesis, using the following
primers: 5′-GGTGGGCAGTGGTGGTGTGGGCAAGAACGCTCTGACTC-
TACAG-3′ and 5′-CTGTAGAGTCAGAGCGTTCTTGCCCACACCAC-
CACTGCCCACC-3′. These primers simultaneously mutated codon 23 of
G23V-RalA to wild-type, and codon 28 from Ser to Asn. DNA sequencing of the
entire insert for a number of clones was performed to confirm the appropriate
mutations present, and to confirm the absence of any PCR-introduced errors.
2.3. Cell culture and transfection
HeLa cells, MCF-7 cells and MCF-7/Adr cells were cultured in DMEM
supplemented with 10% foetal calf serum at 37 °C and 5% CO2 in a humidified
incubator. HeLa cells were plated on glass coverslips and transfected with P-gp-
EGFP alone or with P-gp-EGFP together with either HA-Rab5-S34N, HA-
Rab5-Q79L, HA-RalA-G23Vor HA-RalA-S28N using FuGENE 6 according to
the manufacturer's instructions and analysed 48 h after transfection. HA-Rab5
and HA-RalA mutants were transfected into MCF-7/Adr cells using Lipofectin
(Invitrogen) according to the manufacturer's instructions. Cells were analysed
48 h after transfection.
2.4. Immunocytochemistry
Transiently transfected HeLa or MCF-7/Adr cells were fixed in 4%
paraformaldehyde in PBS. Fixed cells were washed with PBS, and free aldehyde
groups were quenched with 50 mM NH4Cl in PBS. The cells were then
processed for immunolabeling by permeabilisation and labelling in PBS
containing either 0.1% Triton X-100 or 0.1% saponin, and 2% BSA, using
standard procedures. Primary antibodies were detected with Cy3 or Texas Red
conjugated secondary antibodies. Finally, the coverslips were washed and
embedded in mounting media and studied by confocal scanning laser
microscopy using a Radiance Plus (Bio-Rad Laboratory, Hercules, CA) attached
to a Nikon E800 microscope using a NIKON plan Fluor 100×/1.30 oil objective
and Bio-Rad Laser Sharp 2000 program.2.5. Internalisation of EGF and dextran
HeLa cells transfected with P-gp-EGFP and either Rab5-S34N or RalA-
G23V were washed and incubated in DMEM containing 20 mMHEPES/NaOH,
pH 7.4 and 0.1% BSA for 2 h at 37 °C followed by an incubation at 37 °C in the
presence or absence of 0.5 μg/ml EGF-TxR (30 min) or 0.2 mg/ml lysine fixable
dextran-TxR (60 min). Non-bound ligand was removed by extensive washing at
4 °C. Cells were fixed as above and optical sections were analysed by confocal
scanning laser microscopy.
2.6. Intracellular drug accumulation and Confocal Laser Scanning
Microscopy
To study the effect of Rab5 and RalA on intracellular drug accumulation,
transiently transfected HeLa cells were preincubated with or without 25 μM
verapamil for 1 h followed by incubation with 1 μM daunorubicin for 30 min at
37 °C. After the culture medium was removed, the cells were washed with PBS
and the intracellular accumulation of daunorubicin was analysed immediately.
Optical sections were analysed by confocal laser scanning microscopy.
2.7. Quantitative analysis of intracellular P-gp-EGFP and
daunorubicin
For quantitative analysis of cellular drug uptake, the following analysis was
carried out. Cellular drug uptake was measured as the ratio of fluorescence in P-
gp-EGFP expressing cells to that of non transfected HeLa cells in the same field
of view. To allow quantitation, all experiments were carried out under specific
conditions of laser intensity and PMT gains, such that saturation did not occur.
The data were collected at the same magnification and zoom. Each layer of the
3D stack was analysed for the sum of the intensity in the selected field. For the
determination of intracellular daunorubicin intensity, the values of daunorubicin
were first summed and then divided by the sum of intensity of the control cells.
For the intracellular EGFP intensity, these values of EGFP were then summed
Fig. 6. Effect of RalA mutants on the localisation of P-gp-EGFP. HeLa cells were transfected with P-gp-EGFP (green) and either HA-RalA-G23V (A–C) or HA-RalA-
S28N (D–F). Cells were fixed and immunostained for RalA (red). Bar, 5 μm. (G) HeLa cells were transfected with either P-gp-EGFP alone or together with HA-RalA-
G23Vor HA-RalA-S28N. The intracellular fluorescence intensity of P-gp-EGFP was quantified (for details see Materials and methods). ⁎Pb0.01, n=4. (H) HeLa
cells were transfected with P-gp-EGFP and either HA-RalA-G23V or HA-RalA-S28N. The intracellular green fluorescent density (P-gp-EGFP) was measured and
expressed as percentage of total green fluorescence (for details see Materials and methods). The percentage of membrane P-gp-EGFP fluorescence was significantly
decreased (Pb0.001, n=5) when P-gp-EGFP was co-expressed with dominant negative HA-Rab5-S34N. (I) MCF-7/Adr expressing HA-RalA-G23V were fixed and
immunolabelled for P-gp. Bar, 5 μm.
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analysis software package (Carl Zeiss Vision GmbH, Hallbermoos, Germany).
3. Results
3.1. Expression of Rab5 and RalA mutants
We previously reported that an EGFP-tagged P-gp construct
(P-gp-EGFP) is mainly localised to the plasma membrane when
expressed in HeLa cells [4]. In order to manipulate the plasma
membrane localisation of P-gp-EGFP, we set out to compare the
effect of the small GTPases Rab5 and RalA on the trafficking of
P-gp-EGFP, because these GTPases have been described to be
involved in endocytosis. We first expressed HA-Rab5 and HA-
RalA mutants individually in HeLa cells to confirm their
localisation using fluorescent confocol microscopy. As previ-
ously reported [32], constitutively-active HA-Rab5-Q79L was
present in enlarged endosomes (Fig. 1A) whilst the dominant-
negativeHA-Rab5-S34Nwas localised to the cytosol, the ER and
a perinuclear compartment (Fig. 1B). Both constitutively active
HA-RalA-G23V and dominant negative HA-RalA-S28N were
found predominantly at the plasmamembrane and in intracellular
bodies adjacent to the nucleus (Fig. 1C and D, respectively).
3.2. Effects of Rab5 on the intracellular localisation of
P-gp-EGFP
Rab5 is involved in endocytosis and homotypic endosome
fusion and is mainly localised to early endosomes [33]. TheFig. 7. Effect of RalA-G23Vand P-gp-EGFP on endocytosis of TfR and EGF. HeLa c
and immunolabelled for TfR (B). (C) Merged image of A and B. (D–F) P-gp-EGFP a
Bar, 5 μm.simultaneous expression of P-gp-EGFP and constitutively
active Rab5-Q79L was established by co-transfection of HeLa
cells. The intracellular distribution of the Rab5 mutants in cells
co-expressing P-gp-EGFP was similar to the distribution in cells
expressing Rab5 alone, indicating that P-gp-EGFP did not
interfere with cellular localisation of Rab5 mutants (Figs. 1A, B
and 2). P-gp-EGFP was mainly localised to the plasma mem-
brane (Fig. 2A) and this distribution did not change significantly
when P-gp-EGFP was overexpressed together with HA-Rab5-
Q79L (Fig. 2B). However, in some cells a small amount of
P-gp-EGFP was present in enlarged early endosomes (Fig. 2C).
This was confirmed by immuno-staining cells for EEA1, a
marker for early endosomes (Fig. 2D).
In contrast, co-expression of dominant-negative HA-Rab5-
S34N caused a redistribution of P-gp-EGFP to an intracellular
compartment that did not colocalise with HA-Rab5-S34N in
59% of cells (n=220) (Fig. 3A). Quantification of intracellular
P-gp-EGFP in cells co-expressing HA-Rab5-S34N or HA-
Rab5-Q79L showed that cells co-expressing HA-Rab5-S34N
had 10 and 8.9 times higher levels of intracellular P-gp-EGFP
than cells that co-expressed HA-Rab5-Q79L and control P-gp-
EGFP cells, respectively (Pb0.01, n=4) (Fig. 3B). Therefore,
the percentage of plasma membrane bound P-gp-EGFP was
significantly decreased in cells coexpressing P-gp-EGFP and
HA-Rab5-S34N, from 81%±7.6% to 24%±9.8% (Pb0.001,
n=5) compared to cells expressing P-gp-EGFP and HA-
Rab5-Q79L (Fig. 3C).
To confirm these results with wild type P-gp, multidrug
resistance MCF-7/Adr cells were transfected with HA-Rab5-ells were transfected with P-gp-EGFP and HA-RalA-G23V (A). Cells were fixed
nd HA-RalA-G23Vexpressing cells were incubated with EGF-TxR for 30 min.
Fig. 8. Dose dependence and time course of intracellular accumulation of
daunorubicin in MCF-7 cells. (A) HeLa cells were incubated with various
concentrations (0.5, 1, 2, 4 μM) of daunorubicin for 30 min after which
intracellular fluorescence densities were measured (for details see Materials and
methods) and the percentages of cellular fluorescence density were calculated
(relative to 0.5 μM point, n=3). (B) HeLa cells were incubated with 1 μM
daunorubicin for various times (15, 30, 60, 120 min), after which intracellular
fluorescence densities were measure (for details see Materials and methods) and
the percentage of cellular fluorescence density were calculated (relative to
15 min time point, n=3).
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upon expression of HA-Rab5-S34N P-gp was redistributed
from a predominant plasma membrane location to an intracel-
lular compartment (Fig. 3D–E). These data suggest P-gp-EGFP
behaves as wild type P-gp. Dominant negative Rab5 has so far
only been shown to interfere with endocytosis and not enhance
it, as our results suggest. It could therefore be possible that HA-
Rab5-S34N interfered with a different intracellular traffic route.
To test this possibility we first examined in which intracellular
compartment P-gp-EGFP accumulates upon co-expression of
HA-Rab5-S34N.
To examine if P-gp-EGFP accumulates in early endosomes,
cells co-expressing P-gp-EGFP and HA-Rab5-S34N were
labelled for EEA1. Co-expressing cells were selected by the
presence of intracellular P-gp-EGFP. No substantial overlap
between EEA1 and intracellular P-gp-EGFP could be detected
(data not shown). Next, the intracellular localisation of P-gp-
EGFP in cells expressing HA-Rab5-S34N was investigated
using marker proteins for recycling endosomes (TfR), lyso-
somes (LAMP-1), the trans-Golgi Network (Syntaxin 16), the
Golgi complex (Golgin 97 and GS15), mitochondria (mito-
tracker) and the ER (ERp72). Intriguingly, we could demon-
strate only a partial co-localisation of intracellular P-gp-EGFP
with the TfR on the plasma membrane and in the perinuclear
area (Fig. 4A–C), suggesting that P-gp-EGFP accumulates in
recycling endosomes in cells expressing HA-Rab5-S34N. To
examine whether HA-Rab5-S34N had a general effect on
endocytosis in HeLa cells expressing P-gp-EGFP we allowed
uptake of EGF and dextran. As previously shown [20,34], EGF
internalisation was inhibited in cells expressing Rab5-S34N and
co-expression of P-gp-EGFP had no additional effect (Fig. 5A–
C). HA-Rab5-S34N had no effect on internalisation of dextran
and there was overlap between internalised dextran and P-gp-
EGFP, suggesting a common transport route (Fig. 5D–F).
Dextran is targeted into the degradative route, and as no overlap
was found between EEA1 or LAMP-1 (data not shown) and P-
gp-EGFP this suggests the compartment P-gp-EGFP resides in
could be a late endosome. Taken together, these data suggest
that intracellular P-gp-EGFP resides in late endosomes and
recycling endosomes after co-expression of P-gp-EGFP and
HA-Rab5-S34N.
3.3. Effects of RalA mutants on the localisation of P-gp-EGFP
Besides Rab5, the small GTPase RalA has been described to
play a role in endocytosis [31]. To confirm if an enhancement of
endocytosis is the cause of the intracellular accumulation of P-
gp-EGFP upon co-expression of HA-Rab5-S34N we examined
the effect of constitutively-active RalA (HA-RalA-G23V) and
dominant-negative RalA (HA-RalA-S28N) on P-gp-EGFP
localisation. The intracellular distribution of the RalA mutants
in cells co-expressing P-gp-EGFP was the same as the
distribution in cells expressing RalA alone, indicating that P-
gp-EGFP did not interfere with cellular localisation of RalA
mutants (Figs. 1C, D and 6B, E). Interestingly, co-expression of
P-gp-EGFP and constitutively active HA-RalA-G23V resulted
in an intracellular accumulation of P-gp-EGFP in approximately72% of cells (n=200). Furthermore, P-gp-EGFP was localised
to the perinuclear region, mostly overlapping with HA-RalA-
G23V (Fig. 6A–C). The co-expression of dominant-negative
HA-RalA-S28N did not change the intracellular localisation
of P-gp-EGFP, which remained on the plasma membrane
(Fig. 6D–F). Quantitation of fluorescent intensity of EGFP in
cells showed that cells which co-expressed P-gp-EGFP and HA-
RalA-G23V had approximately 18 and 13 times (Pb0.01, n=4)
more intracellular P-gp-EGFP than cells which co-expressed P-
gp-EGFP and HA-RalA-S28N and control P-gp-EGFP cells,
respectively (Fig. 6G). The percentage of plasma membrane
bound P-gp-EGFP was significantly decreased, from 82%±6%
to 31%±12% (Pb0.001, n=5) when P-gp-EGFP was co-
expressed with constitutively active RalA compared to cells co-
expressing dominant negative RalA (Fig. 6H). In addition, wild
type P-gp was also redistributed from the plasma membrane into
an intracellular compartment in multidrug resistant MCF-7/Adr
cells transfected with HA-RalA-G23V (Fig. 6I), suggesting that
P-gp-EGFP behaves as wild type P-gp.
RalA is known to play a role in both receptor mediated
endocytosis and regulated exocytosis [31]. Therefore, the large
intracellular accumulation of P-gp-EGFP could represent either
an increased rate of endocytosis or an inhibition of recycling of
Fig. 9. Expression of Rab5-S34N and RalA-G23V results in increased intracellular accumulation of daunorubicin. HeLa cells were transfected with P-gp-EGFP
(green) alone (C, F) or together with either HA-Rab5-Q79L (A), HA-Rab5-S34N (B), HA-RalA-G23V (D) or HA-RalA-S28N (E). Cells were treated with 1 μM
daunorubicin for 30 min (red A, B, D, E) or cells were treated with 25 μM verapamil for 1 h prior to treatment with 1 μM daunorubicin for 30 min (red, C, F). Bar,
5 μm. (G and H) The intracellular fluorescent intensity of daunorubicin was measured and expressed as percentage of intracellular daunorubicin in non-transfected
cells measured in the same field (for details see Materials and methods) (⁎Pb0.01, n=4).
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intracellular compartment in which P-gp-EGFP resides upon
co-expression of HA-RalA-G23V does not represent the
classical early endosomes because of a lack of overlap with
EEA1 (data not shown). However, intracellular P-gp-EGFP
mostly overlapped with the TfR, suggesting P-gp-EGFP could
be present in recycling endosomes (Fig. 7A–C). Similarly, as
for co-expression of HA-Rab5-S34N, P-gp-EGFP did not
overlap with any other known markers of intracellular
compartments when HA-RalA-G23V was co-expressed (data
not shown). While P-gp-EGFP was redistributed to recycling
endosomes, expression of HA-RalA-G23V inhibited EGF
internalisation in the same cells (Fig. 7D–F). A previous
study also suggested that RalA-G23V could block the
internalisation of EGF [29]. This suggests that unlike EGF, P-
gp-EGFP is not internalised via clathrin-mediated endocytosis.
3.4. Increased accumulation of daunorubicin in HeLa cells
after co-expression of P-gp-EGFP with HA-Rab5-S34N or
HA-RalA-G23V
To examine whether the increased intracellular accumulation
of P-gp-EGFP had any consequences on its function, we
measured the accumulation of daunorubicin, a substrate of P-gp.
To optimize the incubation condition, its time course and dose
dependence were studied (Fig. 8A, B). Results showed that
30 min incubation with 1 μM daunorubicin resulted in an
intracellular accumulation of daunorubicin, which appears as a
punctate pattern. Previous studies also showed a similar
intracellular accumulation pattern and no quenching of the
fluorescence was observed [7,35,36]. With an active P-gp-
EGFP on the plasma membrane most of the daunorubicin is
efficiently pumped out of the cells, while daunorubicin accu-
mulates intracellularly in non-transfected cells (Fig. 9A). How-
ever, in cells co-expressing P-gp-EGFP and HA-Rab5-S34N,
the intracellular accumulation of daunorubicin significantly
increased to similar levels as non-transfected cells (Fig. 9B, G,
Pb0.01). Furthermore, cells treated with the P-gp inhibitor
verapamil also show a similar increase in intracellular dau-
norubicin (Fig. 9C, G). Similar results were obtained when P-gp-
EGFP was co-expressed with HA-RalA-G23V, where HA-RalA-
G23V and P-gp-EGFP coexpression caused an intracellular
accumulation of daunorubicin. By contrast, in HA-RalA-S28N
and P-gp-EGFP coexpressing cells the daunorubicin was
effectively pumped out of the cells (Fig. 9D, E, F, H, Pb0.01).
These results strongly indicate that interfering with the plasma
membrane localisation of P-gp can increase the intracellular
accumulation of P-gp substrate, and could therefore be a potential
way to overcome P-gp-mediated drug resistance.
4. Discussion
Many members of the family of small GTPases, such as
Rab5, Rab4, Rab7, Rab11, Rab15 and RalA, are involved in
regulation of protein trafficking [10,12,31]. In this study we
have compared the effects of Rab5 and RalA and their mutants
on the regulation of the plasma membrane localisation of P-gp-EGFP, as this may provide a method for intervening with P-gp-
mediated drug resistance found in many cancer cells. Rab5
regulates the internalisation of many membrane proteins [19–
23,37] including the cystic fibrosis transmembrane conductance
regulator (CFTR) chloride channel, another member of the
ABC transporter family [38]. A previous study by Kim et al
showed that Rab5 regulates endocytosis and/or recycling of P-
gp in human intestinal cancer cells overexpressing exogenous
canine Rab5 [8] and the present study has extended these
observations. We find that P-gp-EGFP remained largely at the
plasma membrane in HeLa cells co-expressing constitutively
active HA-Rab5-Q79L. This is consistent with reports that
Rab5-Q79L does not significantly facilitate internalisation of
CXCR2, a major chemokine receptor expressed in neutrophils,
nor enhances β2-adrenergic receptor internalisation [22,39].
However, in cells that co-expressed P-gp-EGFP and HA-Rab5-
Q79L, P-gp-EGFP was occasionally observed in enlarged early
endosomes, which labelled for both Rab5 and the early
endosomal marker EEA1. This is consistent with the early
endosome being involved in P-gp-EGFP traffic. Similarly, the
internalised chemokine receptor CXCR2 also co-localised with
Rab5-Q79L. In some cells, increased intracellular P-gp was
observed in early endosomes, which is consistent with a
previous study [8].
Overexpression of dominant-negative HA-Rab5-S34N,
however, resulted in a redistribution of overexpressed P-gp-
EGFP in HeLa cells, a finding also seen with wild type P-gp in
MCF-7/Adr cells. This intracellular accumulation may be due to
either an enhancement of endocytosis or an inhibition of
recycling of P-gp-EGFP back to the plasma membrane.
Intracellular P-gp-EGFP was found to overlap with TfR, a
marker for recycling endosomes, but not early endosomes,
arguing against an effect of Rab5-S34N on endocytosis of P-gp-
EGFP. This is in contrast to previous studies reporting an
inhibition of endocytosis and no effect on recycling by Rab5-
S34N [20,34] and indeed we find that expression of Rab5-S34N
and P-gp-EGFP inhibits EGF internalisation while causing an
increased intracellular localisation of P-gp-EGFP. These data
suggest that P-gp-EGFP is internalised via a different route to
EGF. Co-localisation data showed that the intracellular P-gp-
EGFP was not present in lysosomes, the ER, mitochondria, the
Golgi complex or the TGN. However, a partial overlap between
markers for recycling endosomes (TfR) and the degradative
pathway (dextran) was found. The nature of these intracellular
P-gp-EGFP vesicles needs further investigation.
We also investigated the possibility of RalA being a regulator
of P-gp-EGFP trafficking. The two Ras-like GTPases, RalA and
RalB, have been implicated in the regulation of a variety of
cellular processes including proliferation [40], cell migration
[41], metastasis [42], endocytosis [27,29] and exocytosis [43].
How the Ral proteins regulate endocytosis and exocytosis is still
not clear. Ral-mediated regulation of endocytosis is thought to
be mediated through one of its effector proteins, RalBP1
[27,29], while Ral's influence on exocytosis is mediated
through its interaction with Sec5 and Exo84, a central com-
ponent of the mammalian exocyst complex involved in vesicle
targeting [44,45]. We demonstrated that P-gp-EGFP was mainly
1071D. Fu et al. / Biochimica et Biophysica Acta 1773 (2007) 1062–1072localised at the plasma membrane when co-expressed with
dominant-negative HA-RalA-S28N in HeLa cells. However,
co-expression of P-gp-EGFP and constitutively-active HA-
RalA-G23V resulted in the formation of very large intracellular
vesicles containing P-gp-EGFP and RalA, which were mostly
co-localised under such conditions. Similar effects were seen
with wild type P-gp in MCF-7/Adr cells, where, RalA-G23V
caused a large redistribution of P-gp to an intracellular
compartment. These results suggest that active RalA perturbs
the traffic of P-gp between the plasma membrane and an
intracellular compartment, most likely recycling endosomes. In
cells that co-express P-gp-EGFP and HA-RalA-G23V, the
intracellular P-gp-EGFP did not co-localise with early endo-
somes or Golgi markers. These results are similar to those
obtained for HA-Rab5-S34N. Interestingly, both HA-Rab5-
S34N and HA-RalA-G23V have been described to attenuate
endocytosis, while we find an increased intracellular accumu-
lation of P-gp-EGFP upon co-expression. Possibly, the over-
expression of these proteins interrupted the normal pathway of
P-gp-EGFP before it reached the plasma membrane, resulting in
the intracellular retention of large amounts of P-gp-EGFP.
Our previous studies indicated that intracellular P-gp-EGFP
does not contribute to resistance to anticancer drugs [4,9].
Interruption of P-gp-EGFP traffic by co-expression of HA-
Rab5-S34N or HA-RalA-G23V resulted in the accumulation of
anticancer drug daunorubicin, confirming that the interruption
of the traffic of P-gp could be potentially developed as a new
way to overcome MDR in cancer. Moreover, the interaction
sites of P-gp with Rab5 or RalA could be a potential targets for
the control of P-gp traffic.
In summary, we have demonstrated that the small GTPases
Rab5 and RalA influence the intracellular trafficking of P-gp-
EGFP. Interrupting the traffic of P-gp-EGFP with Rab5 and
RalA mutants resulted in accumulation of a P-gp substrate
anticancer drug. However, since both Rab5 and RalA have
multiple effects on cellular events, further studies are now
needed to confirm the nature of the specific interaction between
P-gp trafficking and these small GTPases.
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